PracticeVideosBlogFlashcardsEspañol
All Practice Exams

Free Practice Questions for Egyptian Board Clinical Pathology

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card
100+ Questions
100% Free

Loading practice questions...

Same family resources

Explore More Egyptian Board Specialty Certifications (البورد المصري)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Egyptian Board — Anesthesia (Part 1 & 2)

Practice Questions

Egyptian Board — Cardiology (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Infectious Diseases (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Oncology (Part 1 & 2)

Practice Questions

Egyptian Board — Critical Care (Part 1 & 2)

Practice Questions

Egyptian Board — Dermatology & Venereology (Part 1 & 2)

Practice Questions
Exam Review

Key Facts: Egyptian Board Clinical Pathology Exam

4 Years

Residency Duration

3 Parts

Exam Stages (Written + OSPE)

Standard-Set

Angoff / Hofstee Scoring

EHC

Examining Authority

The Egyptian Board Clinical Pathology qualification (EHC-EB-PATH) certifies medical laboratory specialists in Egypt. Governed by the Egyptian Health Council under Law No. 12 of 2022 and Decree No. 3798 of 2023, the 4-year residency culminates in Part 1 (basic laboratory sciences) and Part 2 (clinical chemistry, hematology, blood bank, microbiology, and immunology) written MCQ exams, followed by Part 3 OSPE and viva voce. This bank provides 100 targeted practice MCQs for Parts 1 and 2.

Sample Egyptian Board Clinical Pathology Practice Questions

Try these sample questions to review concepts for the Egyptian Board Clinical Pathology exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1During routine morning quality control on an automated clinical chemistry analyzer, the Level 1 control for serum alanine aminotransferase (ALT) produces a value of 88 U/L, which exceeds the established mean (40 U/L, SD = 12 U/L) by 4 standard deviations. Level 2 control is within 1 SD. According to Westgard multirules, what is the primary classification of this violation and the appropriate immediate laboratory action?
A.1:3s rule violation indicating random error; reject the analytical run and halt patient sample testing
B.1:2s warning rule violation; accept the run and inspect the calibration status without halting testing
C.2:2s systematic error violation; rerun patient samples from the previous shift without recalibrating
D.4:1s systematic trend violation; continue patient testing while ordering a fresh reagent pack
Explanation: A control value exceeding the mean by more than 3 standard deviations constitutes a 1:3s Westgard multirule violation. This is a primary rejection rule that characteristically reflects an acute random error, although large systematic shifts can occasionally trigger it. The analytical run must be rejected immediately, patient sample reporting suspended, and troubleshooting initiated prior to re-analysis.
2In a clinical chemistry laboratory evaluating an automated electrolyte analyzer, two consecutive runs of the high-level control material yield serum sodium concentrations that are both +2.3 standard deviations above the target mean. The normal-level control remains at +0.5 SD. Which Westgard rule has been violated and what underlying analytical problem does it represent?
A.R:4s rule reflecting an acute random precision failure between different control levels
B.2:2s rule indicating a systematic analytical error requiring calibration verification
C.1:3s rule signaling an unacceptable pipetting error affecting only the high control
D.10:x rule confirming long-term instrument drift across ten consecutive measurement runs
Explanation: The 2:2s rule is violated when two consecutive control observations exceed either the +2 SD or -2 SD limit, occurring either within the same run across two control levels or across two consecutive runs for the same control level. This rule is highly sensitive to systematic analytical bias or calibration drift. It requires run rejection and systematic error troubleshooting, such as checking calibrator lots, optical alignment, or reagent deterioration.
3A medical technologist reviews the quality control chart for a serum calcium assay utilizing two control levels per analytical run. In the latest run, Level 1 control is measured at +2.2 SD, while Level 2 control is measured at -2.1 SD. What Westgard multirule condition is violated, and what category of analytical error does it indicate?
A.4:1s rule indicating a systematic calibration shift between morning and afternoon runs
B.2:2s rule indicating systematic bias affecting both normal and pathological ranges
C.R:4s rule indicating an unacceptable increase in random analytical error across levels
D.1:2s warning rule permitting the technician to release all patient calcium results
Explanation: The R:4s rule is violated when the difference between two control values within the same analytical run equals or exceeds 4 standard deviations, specifically when one control exceeds +2 SD and the other falls below -2 SD. This rule detects increased random analytical error or imprecision, such as bubble interference, electrical surges, or sample aspiration inconsistency. The run must be rejected and patient results withheld.
4On review of a Levey-Jennings control chart for serum creatinine over the past two weeks, a clinical pathologist notes that ten consecutive daily control measurements have fallen on the positive side of the mean between +0.5 SD and +1.5 SD, with no values exceeding 2 SD. What is the standard Westgard rule interpretation and its root operational implication?
A.The analytical system is in statistical control because all data points are within 2 SD
B.An R:4s violation has occurred, indicating an urgent need to replace the photometer lamp
C.A 1:3s violation is present due to cumulative random variance across consecutive daily runs
D.A 10:x rule violation has occurred, indicating a subtle systematic shift or calibration bias
Explanation: The 10:x rule (or 10:mean rule) is violated when ten consecutive control measurements fall on the same side of the mean, regardless of how small the deviation is. This rule is designed to detect subtle systematic shifts or gradual calibration biases, such as aging calibrator reconstitution, lot-to-lot reagent variations, or detector drift. Although no single point exceeds 2 SD, it requires instrument maintenance or recalibration.
5A routine serum biochemistry panel from an outpatient clinic reveals severe hyperkalemia (potassium 8.4 mmol/L) and profound hypocalcemia (total calcium 1.1 mmol/L), alongside a markedly reduced alkaline phosphatase activity of 6 U/L. The patient is asymptomatic and has normal renal function. What pre-analytical collection error most plausibly explains this pattern?
A.Contamination of the serum sample due to back-transfer from a K2-EDTA collection tube
B.Prolonged tourniquet application causing marked local stasis and cellular hemoconcentration
C.Delayed centrifugation of the unseparated gel tube leading to in vitro erythrocyte leakage
D.Collection of blood into a sodium fluoride-potassium oxalate tube intended for glucose
Explanation: K2-EDTA or K3-EDTA is a potent potassium salt and divalent cation chelator. When blood is poured or splashed from an EDTA tube into a serum tube, or when tubes are collected out of order, the EDTA additive contributes exogenous potassium (causing severe pseudohyperkalemia) and chelates calcium and magnesium (causing profound pseudohypocalcemia). Alkaline phosphatase requires zinc and magnesium as catalytic cofactors; their chelation inactivates the enzyme, producing near-zero measured activity.
6A 3.2% buffered sodium citrate vacutainer tube (light blue top) arrives in the coagulation laboratory filled to only 50% of its nominal fill volume. The automated coagulation analyzer reports a prothrombin time (PT) of 34.0 seconds (INR 3.2) and an activated partial thromboplastin time (aPTT) of 82.0 seconds in a patient with no bleeding history. What is the physiological and analytical mechanism of this result?
A.Platelet activation in the underfilled tube activates tissue factor, consuming clotting factors
B.Citrate evaporation in the vacuum tube increases plasma ionic strength, suppressing thrombin
C.Excess uncomplexed citrate binds calcium reagent in the assay, falsely prolonging clotting times
D.Hemodilution of clotting factors occurs because the anticoagulant volume is disproportionately low
Explanation: Coagulation testing requires an exact 9:1 blood-to-anticoagulant ratio (9 parts whole blood to 1 part 3.2% sodium citrate). In an underfilled tube, the volume of plasma is reduced relative to the volume of liquid citrate, resulting in an excess of free, uncomplexed citrate. When reagent calcium is added during PT and aPTT testing, this excess citrate chelates the reagent calcium, leaving insufficient free calcium to support cascade assembly and leading to artifactually prolonged clotting times.
7A serum specimen shows visible red discoloration corresponding to an in vitro hemolysis index of 350 mg/dL free hemoglobin. Which trio of routine clinical biochemistry analytes will exhibit the most pronounced artifactual elevation as a direct result of erythrocyte intracellular content release?
A.Total calcium, direct bilirubin, and alkaline phosphatase
B.Sodium, serum creatinine, and blood urea nitrogen
C.C-reactive protein, serum albumin, and total cholesterol
D.Potassium, lactate dehydrogenase, and aspartate aminotransferase
Explanation: Erythrocytes contain intracellular concentrations of potassium, lactate dehydrogenase (LDH), and aspartate aminotransferase (AST) that are vastly higher than normal serum levels (erythrocyte-to-plasma ratios are ~25:1 for potassium, ~160:1 for LDH, and ~40:1 for AST). In vitro mechanical or osmotic hemolysis ruptures red blood cells, releasing these constituents into the serum and causing marked false elevations that invalidate diagnostic interpretation.
8A phlebotomist applies a venous tourniquet for three minutes while attempting to locate a vein in a difficult outpatient collection. Which set of laboratory parameters is most susceptible to significant artifactual elevation due to local venous stasis and hemoconcentration?
A.Total calcium, total protein, and albumin
B.Serum sodium, serum chloride, and bicarbonate
C.Blood urea nitrogen, creatinine, and glucose
D.Serum potassium, magnesium, and phosphorus
Explanation: Prolonged tourniquet application (>1 minute) increases intravascular hydrostatic pressure, forcing water and small diffusible filterable ions out of the capillary bed into the interstitial space. Large non-diffusible macromolecules (albumin, total protein, immunoglobulins, enzymes) and substances bound to them—most notably total calcium, which is ~45% bound to albumin—remain concentrated within the vascular lumen, producing clinically significant pseudohypercalcemia and pseudohyperproteinemia.
9A complete blood count (CBC) processed on an automated hematology analyzer yields an RBC count of 1.45 x 10^12/L, Hemoglobin 11.2 g/dL, Hematocrit 14.5%, MCV 128 fL, and an extreme MCHC of 77.2 g/dL. The peripheral smear shows red cell clumps. What is the underlying cause and the required corrective laboratory procedure?
A.Severe microangiopathic hemolysis; report the automated profile and recommend plasmapheresis
B.Severe lipemia interfering with optics; perform a saline replacement centrifugation protocol
C.Cold agglutinin disease; incubate the EDTA blood specimen at 37°C for 15-30 minutes and rerun
D.Hereditary spherocytosis; perform an immediate osmotic fragility test to confirm membrane loss
Explanation: Cold agglutinins are IgM autoantibodies that bind erythrocyte surface antigens at room temperature, causing red blood cells to agglutinate. Automated impedance counters mistake erythrocyte doublets and triplets for single giant cells, leading to a falsely low RBC count, falsely low hematocrit, falsely elevated MCV, and an impossible MCHC (>36-38 g/dL). Warming the EDTA tube to 37°C for 15-30 minutes dissociates the IgM pentamers, disperses agglutinates, and normalizes RBC parameters upon immediate re-analysis.
10A clinical chemist is validating a high-throughput spectrophotometric assay. At high analyte concentrations, the absorbance calibration curve displays a downward plateau (negative deviation from the Beer-Lambert law). Optical inspection reveals that 0.8% of light reaching the photodetector consists of wavelengths outside the nominal bandpass. What is the fundamental physical cause of this limitation?
A.Fluorescence emission by solvent molecules that shifts transmitted light into the UV range
B.Excessive cuvette pathlength causing constructive wave interference in the sample chamber
C.Refraction index matching between the liquid sample and the borosilicate glass cuvette
D.Stray radiant energy (stray light) limiting the maximum measurable analytical absorbance
Explanation: Stray light refers to radiant energy that reaches the detector at wavelengths outside the narrow spectral bandpass transmitted by the monochromator. Because stray light is generally not absorbed by the analyte in the cuvette, it adds a constant background intensity to the transmitted light. At high analyte concentrations (high absorbance), true transmitted light approaches zero, but the non-absorbed stray light continues to strike the detector, creating an apparent upper absorbance ceiling and causing negative deviation from Beer's law.

About the Egyptian Board Clinical Pathology Exam

The Egyptian Board in Clinical Pathology (EHC-EB-PATH) is the national specialist certification in laboratory medicine administered by the Egyptian Health Council under Law No. 12 of 2022. Candidates complete four years of structured clinical laboratory residency before sitting written examinations in basic laboratory sciences (Part 1) and clinical pathology disciplines (Part 2), followed by practical OSPE and oral examinations (Part 3). Please note: Part Three is an in-person OSPE and practical laboratory examination; this 100-question practice bank is an English-language MCQ study aid focusing on laboratory test interpretation, diagnostic algorithms, quality assurance, and clinical correlation across Part 1 and Part 2.

Exam sponsor: Egyptian Health Council — Egyptian Board. The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

The Egyptian Board in Clinical Pathology (الباثولوجيا الإكلينيكية / طب المختبرات) is a 4-year postgraduate training program governed by the Egyptian Health Council (EHC) under Law No. 12 of 2022 and Prime Ministerial Decree No. 3798 of 2023. The certification pathway comprises: Part 1 written examination (laboratory basic sciences: general pathology, biochemistry, medical microbiology, immunology, molecular biology techniques, lab quality and biosafety; held March/August); Part 2 written examination (clinical pathology MCQs: clinical chemistry, clinical hematology, blood banking and transfusion medicine, diagnostic medical microbiology and parasitology, clinical immunology; held April/September); and Part 3 (Objective Structured Practical Examination / OSPE laboratory stations, microscopic slide review, data interpretation, and viva voce oral examination; held December/January).

Time Limit

Varies by examination part

Passing Score

Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published

Exam / Certification Fees

Established by the Egyptian Health Council per annual decree and announced through official candidate registration circulars.

Exam sponsor website

Reported exam pass rate: Not publicly published by the Egyptian Health Council.. Passing standards are established by expert panel consensus using Modified Angoff or Hofstee psychometric methods for written MCQ papers, and Borderline Regression for Part 3 OSPE stations. Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

Part 1 Focus

Laboratory Basic Sciences & Molecular Diagnostics

Cellular injury, apoptosis, genetic inheritance patterns, PCR/RT-qPCR, Sanger and next-generation sequencing, Southern/Western blot principles, and laboratory biosafety levels.

Part 1 & 2

Quality Assurance, Pre-Analytical Variables & Accreditation

Internal quality control (Westgard multirules, Levey-Jennings charts), external quality assessment (EQA/PT), measurement uncertainty, reference intervals, and ISO 15189 compliance.

Part 2 Focus

Clinical Chemistry & Metabolic Medicine

Analytical methods (spectrophotometry, ISE, immunoassay interferences), clinical enzymology, renal/hepatic profiles, blood gases, endocrinology (thyroid, adrenal, pituitary), and toxicology.

Part 2 Focus

Clinical Hematology, Coagulation & Transfusion Medicine

Complete blood count histograms, anemia differential diagnosis, acute/chronic leukemias, myeloproliferative neoplasms, hemostasis assays, antibody screening, crossmatching, and blood component therapy.

Part 2 Focus

Diagnostic Microbiology, Parasitology & Clinical Immunology

Gram-positive/negative identification, antimicrobial susceptibility testing (CLSI/EUCAST breakpoints), viral serology/molecular diagnostics, opportunistic fungal infections, parasitic life cycles, and autoimmune serology.

Preparing for the Egyptian Board Clinical Pathology Exam

What You Need to Know

  • Passing score: Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published
  • Assessment: The Egyptian Board in Clinical Pathology (الباثولوجيا الإكلينيكية / طب المختبرات) is a 4-year postgraduate training program governed by the Egyptian Health Council (EHC) under Law No. 12 of 2022 and Prime Ministerial Decree No. 3798 of 2023. The certification pathway comprises: Part 1 written examination (laboratory basic sciences: general pathology, biochemistry, medical microbiology, immunology, molecular biology techniques, lab quality and biosafety; held March/August); Part 2 written examination (clinical pathology MCQs: clinical chemistry, clinical hematology, blood banking and transfusion medicine, diagnostic medical microbiology and parasitology, clinical immunology; held April/September); and Part 3 (Objective Structured Practical Examination / OSPE laboratory stations, microscopic slide review, data interpretation, and viva voce oral examination; held December/January).
  • Time limit: Varies by examination part
  • Exam / certification fees: Established by the Egyptian Health Council per annual decree and announced through official candidate registration circulars. Official sources

Using Our Practice Resources

  • Work through all 100 available questions
  • Review every answer and explanation
  • Track weak areas and revisit them
  • Use our AI tutor for tough concepts

Egyptian Board Clinical Pathology: Suggested Study Strategy

1Systematically master Westgard multirules (1-3s, 2-2s, R-4s, 4-1s, 10-x) and know how to differentiate random analytical error from systematic calibration drift.
2Review peripheral blood smears and bone marrow differential criteria according to current WHO/ICC classifications for acute leukemias and myeloproliferative disorders.
3Memorize blood bank immunohematology resolution algorithms, including direct antiglobulin test (DAT) workups, antibody identification panels, and transfusion reaction protocols.
4Focus on clinical biochemistry interference patterns, such as hook effects in sandwich immunoassays, heterophile antibodies, and hemolysis/icterus/lipemia (HIL) index flags.
5Solidify knowledge of antimicrobial susceptibility testing guidelines (CLSI M100 and EUCAST), including detection mechanisms for ESBL, carbapenemase (KPC, NDM, OXA-48), and MRSA.

Frequently Asked Questions

What is the Egyptian Board in Clinical Pathology?

The Egyptian Board in Clinical Pathology is the premier national postgraduate certification in laboratory medicine in Egypt, administered by the Egyptian Health Council (EHC) pursuant to Law No. 12 of 2022 and Prime Ministerial Decree No. 3798 of 2023.

What is the structure of the Egyptian Board Clinical Pathology examinations?

The examination comprises three stages: Part 1 covers laboratory basic sciences (biochemistry, medical microbiology, immunology, basic pathology, molecular biology, and lab safety/QC; held March/August); Part 2 tests clinical pathology written MCQs (clinical chemistry, hematology, transfusion medicine, diagnostic microbiology, and clinical immunology; held April/September); and Part 3 consists of OSPE practical laboratory stations, microscopic slide interpretation, and viva voce (held December/January).

How are passing scores determined for the Egyptian Board exams?

Passing cutoffs are established using formal psychometric standard-setting methodologies—primarily the Modified Angoff or Hofstee method for Part 1 and Part 2 written MCQs, and Borderline Regression for Part 3 OSPE stations—rather than fixed percentage thresholds.

Does this question bank cover the Part 3 practical exam?

No. Part Three is an in-person practical examination featuring Objective Structured Practical Examination (OSPE) stations, microscopic slide reading, and oral viva voce. This online practice bank provides 100 high-yield English-language MCQs designed specifically to prepare candidates for the written knowledge and data interpretation components of Part 1 and Part 2.

What are the eligibility criteria to sit the Egyptian Board examinations?

Candidates must hold an MBBCh or equivalent medical degree, have completed a recognized rotating internship year, be licensed by the Egyptian Ministry of Health and Population and registered with the Egyptian Medical Syndicate, and be actively enrolled in an accredited 4-year EHC Clinical Pathology residency training center.